Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

259.88 -3.73 (-1.41%)
Streaming Delayed Price Updated: 1:21 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 Next >
News headline image
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
From BeOne Medicines Ltd
Via Business Wire
News headline image
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at Upcoming Investor Conferences
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
From BeOne Medicines Ltd.
Via Business Wire
News headline image
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at Upcoming Investor Conferences
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From BeOne Medicines Ltd.
Via Business Wire
News headline image
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
From BeOne Medicines Ltd.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.